nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
June 17, 2024 08:26 ET | Novo Nordisk A/S
Bagsværd, Denmark, 17 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
June 10, 2024 08:15 ET | Novo Nordisk A/S
Bagsværd, Denmark, 10 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
June 03, 2024 10:05 ET | Novo Nordisk A/S
Bagsværd, Denmark, 3 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
May 27, 2024 08:49 ET | Novo Nordisk A/S
Bagsværd, Denmark, 27 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
May 17, 2024 10:20 ET | Novo Nordisk A/S
Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
May 15, 2024 07:23 ET | Novo Nordisk A/S
Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
May 13, 2024 11:49 ET | Novo Nordisk A/S
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
May 08, 2024 11:31 ET | Novo Nordisk A/S
Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
nn_logo_cmyk_blue_small.jpg
Trading in Novo Nordisk shares by board members, executives and associated persons
May 06, 2024 15:02 ET | Novo Nordisk A/S
Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
May 06, 2024 14:44 ET | Novo Nordisk A/S
Bagsværd, Denmark, 06 May 2024 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new...